	US 12,351,644 B2
	Anti-CD73 antibodies
Emily Piccione Griffin, Belmont, CA (US); Richard A. Miller, Portola Valley, CA (US); and Ian McCaffery, Oakland, CA (US)
Assigned to Corvus Pharmaceuticals, Inc., Burlingame, CA (US)
Filed by CORVUS PHARMACEUTICALS, INC., Burlingame, CA (US)
Filed on Aug. 27, 2020, as Appl. No. 17/005,051.
Application 17/005,051 is a continuation of application No. 15/647,212, filed on Jul. 11, 2017, granted, now 10,793,636.
Claims priority of provisional application 62/395,875, filed on Sep. 16, 2016.
Claims priority of provisional application 62/360,804, filed on Jul. 11, 2016.
Prior Publication US 2021/0221905 A1, Jul. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

11 Claims

1. An anti-CD73 antibody comprising:

(i) a light chain variable domain comprising a CDR L1 comprising the amino acid sequence of SEQ ID NO:1, but for the replacement of the asparagine residue therein with an amino acid residue selected from alanine, glycine, glutamine, and aspartic acid, a CDR L2 comprising the amino acid sequence of SEQ ID NO:2 and a CDR L3 comprising the amino acid sequence of SEQ ID NO:3; and

(ii) a heavy chain variable domain comprising a CDR H1 comprising the amino acid sequence of SEQ ID NO:4, a CDR H2 comprising the amino acid sequence of SEQ ID NO:5 and a CDR H3 comprising the amino acid sequence of SEQ ID NO:6.